Bevacizumab Combined With Fractionated Stereotactic Radiotherapy for 1 to 10 Brain Metastases From NSCLC : A Prospective, Phase II Study of Bevacizumab Combined With Fractionated Stereotactic Radiotherapy in Patients With 1 to 10 Brain Metastases From Non-small Cell Lung Cancer
This Phase II randomized study is to determine the efficacy and safety of Bevacizumab combined with fractionated stereotactic radiation therapy(FSRT) in patients with 1 to 10 brain metastases in non-small cell lung cancer by assessing the treatment response, neurological symptoms and quality of life.Patients will receive Bevacizumab(7.5mg/kg, q3w, i.v.) before and after FSRT(40Gy in 10 fractions or 30Gy in 5 fractions) to the brain metastases. The primary endpoint was intra-cranial progression-free survival (IPFS). Secondary endpoints included overall survival (OS), progression-free survival (PFS), quality of life (QOL) scores, and toxicities..
Medienart: |
Klinische Studie |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
ClinicalTrials.gov - (2023) vom: 28. Aug. Zur Gesamtaufnahme - year:2023 |
---|
Sprache: |
Englisch |
---|
Links: |
Volltext [kostenfrei] |
---|
Themen: |
610 |
---|
Anmerkungen: |
Source: Link to the current ClinicalTrials.gov record., First posted: April 14, 2020, Last downloaded: ClinicalTrials.gov processed this data on September 06, 2023, Last updated: September 06, 2023 |
---|
fisyears: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
CTG003358631 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | CTG003358631 | ||
003 | DE-627 | ||
005 | 20230906010408.0 | ||
007 | cr uuu---uuuuu | ||
008 | 210408s2023 xx |||||o 00| ||eng c | ||
035 | |a (DE-627)CTG003358631 | ||
035 | |a (UBBS_Klinische_Studien)NCT04345146 | ||
035 | |a (UBBS_Klinische_Studien)GASTO-1053 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
245 | 1 | 0 | |a Bevacizumab Combined With Fractionated Stereotactic Radiotherapy for 1 to 10 Brain Metastases From NSCLC |b A Prospective, Phase II Study of Bevacizumab Combined With Fractionated Stereotactic Radiotherapy in Patients With 1 to 10 Brain Metastases From Non-small Cell Lung Cancer |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Source: Link to the current ClinicalTrials.gov record., First posted: April 14, 2020, Last downloaded: ClinicalTrials.gov processed this data on September 06, 2023, Last updated: September 06, 2023 | ||
520 | |a This Phase II randomized study is to determine the efficacy and safety of Bevacizumab combined with fractionated stereotactic radiation therapy(FSRT) in patients with 1 to 10 brain metastases in non-small cell lung cancer by assessing the treatment response, neurological symptoms and quality of life.Patients will receive Bevacizumab(7.5mg/kg, q3w, i.v.) before and after FSRT(40Gy in 10 fractions or 30Gy in 5 fractions) to the brain metastases. The primary endpoint was intra-cranial progression-free survival (IPFS). Secondary endpoints included overall survival (OS), progression-free survival (PFS), quality of life (QOL) scores, and toxicities. | ||
650 | 2 | |a Lung Neoplasms | |
650 | 2 | |a Carcinoma, Non-Small-Cell Lung | |
650 | 2 | |a Neoplasm Metastasis | |
650 | 2 | |a Brain Neoplasms | |
650 | 4 | |a Study Type: Interventional | |
650 | 4 | |a Recruitment Status: Completed | |
650 | 4 | |a Phase: Phase 2 | |
650 | 4 | |a 610 | |
773 | 0 | 8 | |i Enthalten in |t ClinicalTrials.gov |g (2023) vom: 28. Aug. |
773 | 1 | 8 | |g year:2023 |g day:28 |g month:08 |
856 | 4 | 0 | |u https://clinicaltrials.gov/show/NCT04345146 |z kostenfrei |3 Volltext |
912 | |a GBV_CTG | ||
951 | |a AR | ||
952 | |j 2023 |b 28 |c 08 |